Novartis International AG Diabetes Drug Galvus Approved in Europe
ZURICH, Sept 28 (Reuters) - Novartis AG's (NOVN.VX: Quote, Profile, Research) potential blockbuster diabetes treatment Galvus has been approved for use in the European Union, the Swiss drugmaker said on Friday.